company background image
A068270 logo

Celltrion KOSE:A068270 Stock Report

Last Price

₩158.70k

Market Cap

₩33.8t

7D

3.4%

1Y

-6.0%

Updated

29 May, 2025

Data

Company Financials +

A068270 Stock Overview

Develops and produces drugs based on proteins for the treatment of oncology in South Korea. More details

A068270 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Celltrion, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Celltrion
Historical stock prices
Current Share Price₩158,700.00
52 Week High₩200,952.38
52 Week Low₩150,400.00
Beta0.58
1 Month Change-3.23%
3 Month Change-13.75%
1 Year Change-6.02%
3 Year Change10.03%
5 Year Change-27.00%
Change since IPO1,576.81%

Recent News & Updates

Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

May 03
Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Apr 09
Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Recent updates

Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

May 03
Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Apr 09
Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

Jan 06
Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

Is Celltrion (KRX:068270) A Risky Investment?

Dec 10
Is Celltrion (KRX:068270) A Risky Investment?

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Jun 26
Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Shareholder Returns

A068270KR BiotechsKR Market
7D3.4%1.5%1.5%
1Y-6.0%20.2%-3.0%

Return vs Industry: A068270 underperformed the KR Biotechs industry which returned 20.2% over the past year.

Return vs Market: A068270 underperformed the KR Market which returned -3% over the past year.

Price Volatility

Is A068270's price volatile compared to industry and market?
A068270 volatility
A068270 Average Weekly Movement4.5%
Biotechs Industry Average Movement8.4%
Market Average Movement6.2%
10% most volatile stocks in KR Market12.5%
10% least volatile stocks in KR Market3.0%

Stable Share Price: A068270 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A068270's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,391Hyong-Gi Kimwww.celltrion.com

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis.

Celltrion, Inc. Fundamentals Summary

How do Celltrion's earnings and revenue compare to its market cap?
A068270 fundamental statistics
Market cap₩33.84t
Earnings (TTM)₩508.92b
Revenue (TTM)₩3.66t
66.5x
P/E Ratio
9.2x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A068270 income statement (TTM)
Revenue₩3.66t
Cost of Revenue₩1.84t
Gross Profit₩1.82t
Other Expenses₩1.31t
Earnings₩508.92b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)2.39k
Gross Margin49.64%
Net Profit Margin13.90%
Debt/Equity Ratio12.7%

How did A068270 perform over the long term?

See historical performance and comparison

Dividends

0.5%
Current Dividend Yield
30%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 19:46
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celltrion, Inc. is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Dae Woong YooBookook Securities Co. Ltd
Aaron HoCFRA Equity Research